Stock Track | Madrigal Pharmaceuticals Soars 8.24% in Pre-market on Promising Rezdiffra Data and Better-Than-Expected Q4 Results

Stock Track

Feb 26, 2025

Shares of Madrigal Pharmaceuticals (MDGL) surged 8.24% in the pre-market trading session on Wednesday, February 26, 2025, driven by the company's promising clinical trial data for its drug Rezdiffra and better-than-expected financial results for the fourth quarter of 2024.

Madrigal reported positive two-year data from the open-label compensated MASH (metabolic dysfunction-associated steatohepatitis) cirrhosis arm of the Phase 3 MAESTRO-NAFLD-1 trial. Patients treated with Rezdiffra achieved a mean 6.7 kPa reduction in liver stiffness, the largest reported reduction in a compensated MASH cirrhosis population to date. This data reinforces the potential benefit of Rezdiffra in treating this underserved patient population with no approved therapies.

Additionally, the company reported fourth-quarter 2024 revenue of $103.3 million, exceeding analyst estimates of $99.1 million, and a narrower net loss of $2.71 per share compared to the expected loss of $4.12 per share. Madrigal ended the year with a strong cash position of $931.3 million, positioning the company for continued growth and expansion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1112394305"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1112394305\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1112394305?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-26 22:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112394305","market":"us","top_or_hot":-1,"title":"Stock Track | Madrigal Pharmaceuticals Soars 8.24% in Pre-market on Promising Rezdiffra Data and Better-Than-Expected Q4 Results","media":"Stock Track","content":"<p>Shares of Madrigal Pharmaceuticals (MDGL) surged 8.24% in the pre-market trading session on Wednesday, February 26, 2025, driven by the company's promising clinical trial data for its drug Rezdiffra and better-than-expected financial results for the fourth quarter of 2024.</p>\n\n<p>Madrigal reported positive two-year data from the open-label compensated MASH (metabolic dysfunction-associated steatohepatitis) cirrhosis arm of the Phase 3 MAESTRO-NAFLD-1 trial. Patients treated with Rezdiffra achieved a mean 6.7 kPa reduction in liver stiffness, the largest reported reduction in a compensated MASH cirrhosis population to date. This data reinforces the potential benefit of Rezdiffra in treating this underserved patient population with no approved therapies.</p>\n\n<p>Additionally, the company reported fourth-quarter 2024 revenue of $103.3 million, exceeding analyst estimates of $99.1 million, and a narrower net loss of $2.71 per share compared to the expected loss of $4.12 per share. Madrigal ended the year with a strong cash position of $931.3 million, positioning the company for continued growth and expansion.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Madrigal Pharmaceuticals Soars 8.24% in Pre-market on Promising Rezdiffra Data and Better-Than-Expected Q4 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Madrigal Pharmaceuticals Soars 8.24% in Pre-market on Promising Rezdiffra Data and Better-Than-Expected Q4 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-26 22:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Madrigal Pharmaceuticals (MDGL) surged 8.24% in the pre-market trading session on Wednesday, February 26, 2025, driven by the company's promising clinical trial data for its drug Rezdiffra and better-than-expected financial results for the fourth quarter of 2024.</p>\n\n<p>Madrigal reported positive two-year data from the open-label compensated MASH (metabolic dysfunction-associated steatohepatitis) cirrhosis arm of the Phase 3 MAESTRO-NAFLD-1 trial. Patients treated with Rezdiffra achieved a mean 6.7 kPa reduction in liver stiffness, the largest reported reduction in a compensated MASH cirrhosis population to date. This data reinforces the potential benefit of Rezdiffra in treating this underserved patient population with no approved therapies.</p>\n\n<p>Additionally, the company reported fourth-quarter 2024 revenue of $103.3 million, exceeding analyst estimates of $99.1 million, and a narrower net loss of $2.71 per share compared to the expected loss of $4.12 per share. Madrigal ended the year with a strong cash position of $931.3 million, positioning the company for continued growth and expansion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDGL","symbol_name":"Madrigal Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1112394305","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112394305","pubTimestamp":1740581069,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Madrigal Pharmaceuticals  surged 8.24% in the pre-market trading session on Wednesday, February 26, 2025, driven by the company's promising clinical trial data for its drug Rezdiffra and better-than-expected financial results for the fourth quarter of 2024.Madrigal reported positive two-year data from the open-label compensated MASH  cirrhosis arm of the Phase 3 MAESTRO-NAFLD-1 trial. Patients treated with Rezdiffra achieved a mean 6.7 kPa reduction in liver stiffness, the largest repo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDGL":"Madrigal Pharmaceuticals, Inc."},"translate_title":"由于Rezdiffra数据乐观且第四季度业绩好于预期，Madrigal Pharmaceuticals盘前股价飙升8.24%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDGL":1},"content_text":"Shares of Madrigal Pharmaceuticals (MDGL) surged 8.24% in the pre-market trading session on Wednesday, February 26, 2025, driven by the company's promising clinical trial data for its drug Rezdiffra and better-than-expected financial results for the fourth quarter of 2024.\nMadrigal reported positive two-year data from the open-label compensated MASH (metabolic dysfunction-associated steatohepatitis) cirrhosis arm of the Phase 3 MAESTRO-NAFLD-1 trial. Patients treated with Rezdiffra achieved a mean 6.7 kPa reduction in liver stiffness, the largest reported reduction in a compensated MASH cirrhosis population to date. This data reinforces the potential benefit of Rezdiffra in treating this underserved patient population with no approved therapies.\nAdditionally, the company reported fourth-quarter 2024 revenue of $103.3 million, exceeding analyst estimates of $99.1 million, and a narrower net loss of $2.71 per share compared to the expected loss of $4.12 per share. Madrigal ended the year with a strong cash position of $931.3 million, positioning the company for continued growth and expansion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}